DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients. Offered by Defense Health Agency Contracting Activity - DHACA; awards $7.0M; applications due September 30, 2026.